Science News from ESC 2015

SCIENCE NEWS - covering the science presented daily at ESC Congress 2015 with exclusive video interviews, summary slides for late-breaking clinical trials presented in Hot Line sessions, and links to AHA science and resources related to the Hot Line science each day.

For more information and press releases, visit the AHA|ASA Newsroom.

Mark Creager, MD, president of the American Heart Association, and Kim Allan Williams, Sr, MD, president of the American College of Cardiology, review some of the highlights of the science presented this week at the European Society of Cardiology Congress 2015.

Mark Creager, MD, president of the American Heart Association and Bob Bonow, MD and Elliott Antman, MD, both past presidents, review the science on acute myocardial infarction presented in Hot Line I.

Mark Creager, MD, president of the American Heart Association and Bob Bonow, MD and Elliott Antman, MD, both past presidents, discuss the Atrial Fibrillation and Pacing science presented in Hotline II at the European Society of Cardiology Congress 2015 in London, including LEADLESS II and BELIEF.

Hot Line I: Acute myocardial infarction

DOPPLER-CIP – Determining Optimal non-invasive Parameters for the Prediction of Left vEntricular morphologic and functional Remodelling in Chronic Ischemic Patients

Hot Line II: Atrial Fibrillation/Pacing

EAST-AF/UNDER-ATP – Kansai Plus Atrial Fibrillation Trial (KPAF)

BELIEF – Effect of empirical electrical left atrial appendage isolation on long-term procedure outcome in patients with long-standing persistent atrial fibrillation undergoing catheter ablation

AEGEAN – Assessment of an education and guidance program for apixaban adherence in non-valvular atrial fibrillation

LEADLESS II – Safety and efficacy of a leadless pacemaker

Mark Creager, MD, president of the American Heart Association, and Mariell Jessup, MD review some of the science presented at Hot Line III at the European Society of Cardiology Congress 2015 in London, including SCOT, TECOS, and ELIXA.

Mariell Jessup, MD and Mark Creager, MD, president of the American Heart Association, review the some of the science presented in Hot Line IV at the European Society of Cardiology Congress 2015 in London, including PATHWAY-2, PATHWAY-3 and PARAMETER.

Hot Line III: Diabetes Mellitus/Pharmacology

ELIXA – This study investigates the efficacy of lixisenatide in the context of acute coronary syndromes.

SCOT – The Standard care versus Celecoxib Outcome Trial

Hot Line IV: Hypertension

PATHWAY 2/ PATHWAY-3 – These two trials investigate the possibility of using an algorithm-based therapy for treating drug-resistant hypertension.

PARAMETER – Principal results of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the elderly

Mark Creager, MD, president of the American Heart Association, and Mariell Jessup, MD, discuss OptiLink HF and SERVE-HF which were presented in Hot Line V on Heart Failure at the European Society of Cardiology Congress 2015.

Mark Creager, MD, president of the American Heart Association, and Elliott Antman, MD discuss trials presented at Hot Line VI on Coronary Artery Disease at the European Society of Cardiology Congress 2015, including PRESERVATION I, ABSORB STEMI TROFI II, and ABSORB Japan.

Hot Line V: Heart Failure

OptiLink HF – Effect of implanted device-based impedance monitoring with telemedicine alerts on mortality and morbidity in heart failure

SERVE-HF – In this multinational, multicenter, randomized controlled, Phase III trial, using adaptive servo-ventilation (ASV) therapy to treat moderate to severe sleep apneas in addition to optimized medical care failed to reduce mortality and morbidity in patients with symptomatic chronic heart failure.

BENEFIT – The BENznidazole Evaluation For Interrupting Trypanosomiasis trial

Hot Line VI: Coronary Artery Disease

ABSORB – This Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial evaluates the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions in Japanese population by comparing to approved metallic drug eluting stent.